Myocardial Injury Pattern at MRI in COVID-19 Vaccine–associated Myocarditis

Matteo Fronza, MD • Paaladinesh Thavendiranathan, MD, SM • Victor Chan, MD • Gauri Rani Karan, MD • Jacob A. Udell, MD, MPH • Rachel M. Wald, MD • Rachel Hong, BSc • Kate Hanneman, MD, MPH

From the Department of Medical Imaging (M.F., P.T., V.C., G.R.K., R.M.W., R.H., K.H.) and Division of Cardiology (J.A.U., R.M.W.) and Toronto General Hospital, Peter Munk Cardiac Centre, University Health Network (UHN), University of Toronto, 585 University Ave, 1 PMB-298, Toronto, ON, Canada M5G 2N2; and Department of Medical Imaging (M.F., P.T., V.C., G.R.K., R.M.W.) and Cardiovascular Division (J.A.U.), Women’s College Hospital, University of Toronto, Toronto, Canada. Received October 9, 2021; revision requested November 22; revision received December 29; accepted January 20, 2022. Address correspondence to K.H. (email: kate.hanneman@uhn.ca).

Supported by a grant from the Joint Division of Medical Imaging, Canadian Radiological Foundation (CRF), and the Canadian Heads of Academic Radiology (CHAR). P.T. supported by a Canada Research Chair in Cardio-oncology. J.A.U. supported by a Department of Medicine, University of Toronto Merit Award and an Ontario Ministry of Colleges and Universities Early Researcher Award (ER15-11-037).

Conflicts of interest are listed at the end of this article.

See also the editorial by Raman and Neubauer in this issue.

Background: There are limited data on the pattern and severity of myocardial injury in patients with COVID-19 vaccination–associated myocarditis.

Purpose: To describe myocardial injury following COVID-19 vaccination and to compare these findings to other causes of myocarditis.

Materials and Methods: In this retrospective cohort study, consecutive adult patients with myocarditis with at least one T1-based and at least one T2-based abnormality at cardiac MRI performed at a tertiary referral hospital from December 2019 to November 2021 were included. Patients were classified into one of three groups: myocarditis following COVID-19 vaccination, myocarditis following COVID-19 illness, and other myocarditis not associated with COVID-19 vaccination or illness.

Results: Of the 92 included patients, 21 (23%) had myocarditis following COVID-19 vaccination (mean age, 31 years ± 14 [SD]; 17 men; messenger RNA–1273 in 12 [57%] and BNT162b2 in nine [43%]). Ten of 92 (11%) patients had myocarditis following COVID-19 illness (mean age, 51 years ± 14; three men) and 61 of 92 (66%) patients had other myocarditis (mean age, 44 years ± 18; 36 men). MRI findings in the 21 patients with vaccine-associated myocarditis included late gadolinium enhancement (LGE) in 17 patients (81%) and left ventricular dysfunction in six (29%). Compared with other causes of myocarditis, patients with vaccine-associated myocarditis had a higher left ventricular ejection fraction and less extensive LGE, even after controlling for age, sex, and time from symptom onset to MRI. The most frequent location of LGE in all groups was subepicardial at the basal inferolateral wall, although septal involvement was less common in vaccine-associated myocarditis. At short-term follow-up (median, 22 days [IQR, 7–48 days]), all patients with vaccine-associated myocarditis were asymptomatic with no adverse events.

Conclusion: Cardiac MRI demonstrated a similar pattern of myocardial injury in vaccine-associated myocarditis compared with other causes, although abnormalities were less severe, with less frequent septal involvement and no adverse events over the short-term follow-up.

© RSNA, 2022

Online supplemental material is available for this article.

Myocarditis is a nonischemic inflammatory disease of the myocardium that has diverse causes, clinical patterns, and outcomes (1). Characteristic features are inflammation and myocyte damage, which may be mediated both by direct invasion of the myocardium in the setting of viral infection and by the host’s immune response (2). Acute myocarditis is more common in men compared with women, although the incidence is difficult to establish as the clinical presentation is often nonspecific and endomyocardial biopsy is not routinely performed (3).

Myocarditis following immunization is a rare event that has received increased attention recently due to reports of myocardial injury in a minority of patients after receiving messenger RNA (mRNA)–based COVID-19 vaccines (4,5). As of December 2021, more than 4.5 billion people worldwide had received a dose of a COVID-19 vaccine (6). Therefore, serious adverse events associated with administration of vaccines targeting COVID-19 are highly relevant to the public, clinicians, and other policy makers, even if the incidence is rare. Importantly, COVID-19 illness can also result in myocardial injury, which is associated with adverse outcomes in hospitalized patients and should be balanced against the risk of vaccine-related complications (7,8).

Cardiac MRI has an important role in the assessment of acute myocarditis with unparalleled ability for noninvasive characterization of myocardial tissue (9). Several recent case series have described MRI findings in hospitalized patients with myocarditis following COVID-19 vaccination (10–12). However, there are limited data on the extent of myocardial injury in comparison to other causes of myocarditis, particularly in nonhospitalized patients. Understanding the pattern and extent of myocardial injury and its implications will allow for improved care of these patients.
patients and may help address vaccine hesitancy. The aim of this study was to determine the pattern and extent of MRI findings in myocarditis associated with COVID-19 vaccination and to compare these findings with other causes of myocarditis.

Materials and Methods

Study Design and Participants

This retrospective cohort study was approved by the institutional ethics committee, and the requirement for written informed consent was waived. Hospitalized or nonhospitalized consecutive adult patients (≥18 years of age) who were referred to a tertiary hospital network for evaluation of myocarditis with cardiac MRI from December 2019 to November 2021 were identified. Inclusion criteria were fulfillment of the clinical presentation and diagnostic testing criteria of the European Society of Cardiology for clinically suspected myocarditis (13) and both of the main revised Lake Louise criteria for nonischemic myocardial inflammation on MRI scans (at least one T1-based criteria and at least one T2-based criteria; additional details are provided in Appendix E1 [online]) (14). The exclusion criterion was MRI performed for follow-up of previously diagnosed myocarditis.

Demographic characteristics, vaccine administration, medications, blood test results, electrocardiographic parameters, and clinical outcomes data were extracted from the electronic patient record. Patients were classified into one of three groups:

- Patients with COVID-19 vaccine–associated myocarditis (symptom onset within 14 days of vaccine administration with no other cause of myocarditis identified), COVID-19 illness–associated myocarditis (symptom onset within 14 days of confirmed SARS-COV-2 infection based on reverse transcriptase–polymerase chain reaction assays of nasopharyngeal swabs with no other cause of myocarditis identified), and other myocarditis (all other patients meeting the inclusion criteria without temporally associated COVID-19 vaccine administration or known COVID-19 illness) (15,16).

MRI Analysis

MRI studies were analyzed independently by two experienced fellowship-trained observers (M.F. and V.C., both with 2 years of cardiac imaging experience) who were blinded to all clinical information with commercially available tools (Circle cvi42; Circle Cardiovascular Imaging). Ventricular volume, function, and mass were measured using semiautomated contour detection with manual correction, if required, per established standards (20). Global longitudinal, circumferential, and radial strain (global longitudinal strain [three long-axis views], global radial strain, and global circumferential strain [entire short-axis stack, respectively]) were calculated from balanced steady-state free precession images by using feature tracking strain analysis. The presence of LGE and regional T2-weighted hyperintensity was evaluated visually (present or not), globally, and according to the American Heart Association 17-segment model (21). For assessment of LGE, the predominant pattern was classified as subendocardial, midwall, subepicardial, or transmural. LGE was quantified using a signal-intensity threshold of 4 SDs above visually normal reference myocardium, expressed in grams and as a percentage of left ventricular mass. Source T1 and T2 mapping images were examined for artifacts, and any segments with an artifact were excluded from analysis. Septal T1 and T2 relaxation times were assessed by manually drawing a region of interest at the midinterventricular septum, avoiding the right ventricular insertion points and blood pool. Maximum T1 and T2 values were also measured by manually drawing a region of interest in areas of visually maximum myocardial values based on the color map, with a minimum region of interest size of 0.5 cm². Per current guidelines, abnormal maximum T1 and T2 values were defined as 2 SDs above the mean of sequence-specific local ref-
of vaccine-associated myocarditis were younger and more frequently male compared with the other groups. The median time from symptom onset to MRI was 11 days (IQR, 4–29 days).

Among the 21 patients with vaccine-associated myocarditis, COVID-19 vaccination included LGE in 17 of 21 (81%), high T2 in 16 of 21 (76%), hyperintense signal on T2-weighted images in 15 of 19 (79%), and systolic left ventricular dysfunction (left ventricular ejection fraction [LVEF] <55%) in six of 21 (29%) (Fig 2). In all patients with myocarditis after vaccination (n = 21), at least one T2-based abnormality colocalized within the same myocardial segment as a T1-based abnormality, including LGE. None of the MRI parameters differed significantly between vaccine types.

The peak high-sensitivity cardiac troponin I level correlated significantly with the maximum native T2 z score (r = 0.50, P = .040), LVEF (r = −0.58, P = .015), global circumferential strain (r = 0.66, P = .005), and global radial strain (r = −0.59, P = .013) but not with the maximum native T1 z score, LGE extent, or global longitudinal strain.

Comparison of COVID-19 and Other Causes of Myocarditis
Compared with patients with other causes of myocarditis, patients with vaccine-associated myocarditis had a significantly
higher LVEF and right ventricular ejection fraction; less impaired global longitudinal strain, global circumferential strain, and global radial strain; lower native T1; and less extensive LGE (Fig 3, Table 2). Differences in the LVEF, global longitudinal strain, global circumferential strain, global radial strain, native T1, and LGE extent remained significant even after controlling for patient age, sex, and time from symptom onset to imaging (Table 3). Compared with patients with COVID-19 illness, patients with vaccine-associated myocarditis had a higher LVEF, less regional wall motion abnormalities, and lower native T1. Differences in LVEF remained significant even in the multivariable model. In all three patient groups, the most frequent pattern of LGE was subepicardial and the most frequent myocardial segment involved was the basal inferolateral wall (Fig 4). However, patients with COVID-19 illness and other myocarditis had a higher prevalence of abnormalities involving the basal to mid anterior and inferior septum, while patients with vaccine-associated myocarditis rarely had abnormalities involving the anterior wall or septum. There were no significant differences in blood biomarkers or electrocardiographic parameters between groups.

**Sensitivity Analysis**
Conclusions of our primary analyses were unchanged when we excluded the two patients who had vaccine-associated myocarditis with a history of COVID-19 illness (Table E1 [online]), and when the other myocarditis group was restricted to patients with non-COVID-19 viral or postinfectious myocarditis (Table E2 [online]).

**Follow-up**
All patients with vaccine-associated myocarditis had short-term clinical follow-up for a median of 22 days (IQR, 7–48 days).
Table 2: Cardiac MRI Findings

| Parameter                                      | All Patients (n = 92) | COVID-10 Vaccine Group (n = 21) | COVID-19 Illness Group (n = 10) | Other Myocarditis Group (n = 61) | P Value |
|------------------------------------------------|-----------------------|--------------------------------|--------------------------------|----------------------------------|---------|
| Left ventricle                                 |                       |                                |                                |                                  |         |
| LVEDVI (mL/m²)                                 | 85 (71–97)            | 79 (69–87)                     | 81 (72–98)                     | 88 (71–97)                       | .26     |
| LVESVI (mL/m²)                                 | 40 (32–49)            | 35 (29–40)                     | 36 (31–47)                     | 43 (34–55)*                      | .006    |
| LVMI (g/m²)                                    | 59 (47–68)            | 51 (46–61)                     | 48 (40–59)                     | 62 (50–76)*                      | .01     |
| LVEF (%)                                       | 52 (46–57)            | 58 (53–59)                     | 55 (49–57)*                    | 50 (41–54)*                      | <.001   |
| GLS (%)                                        | -14 (±17 to -11)      | -16 (±19 to -14)               | -17 (±17 to -15)               | -13 (±15 to -10)*                | <.001   |
| GCS (%)                                        | -15 (±17 to -12)      | -16 (±19 to -15)               | -17 (±18 to -15)               | -14 (±16 to -10)*                | <.001   |
| GRS (%)                                        | 23 (17–28)            | 26 (22–31)                     | 28 (23–30)                     | 21 (14–25)*                      | <.001   |
| Low LVEF†                                      | 58 (63)               | 6 (29)                         | 5 (50)                         | 47 (77)*                         | <.001   |
| Regional wall motion abnormality†              | 30 (33)               | 0 (0)                          | 4 (40)*                        | 26 (43)*                         | <.001   |
| Right ventricle                                |                       |                                |                                |                                  |         |
| RVEDVI (mL/m²)                                 | 82 (70–97)            | 84 (71–100)                    | 82 (70–95)                     | 82 (69–96)                       | .95     |
| RVESVI (mL/m²)                                 | 40 (31–48)            | 38 (32–46)                     | 35 (28–44)                     | 42 (31–50)                       | .46     |
| RVEF (%)                                       | 51 (47–55)            | 54 (51–54)                     | 55 (53–59)                     | 51 (45–55)*                      | .02     |
| Left atrial area (cm²)                         | 22 (19–26)            | 20 (16–22)                     | 24 (22–28)                     | 22 (19–27)                       | .04     |
| Right atrial area (cm²)                        | 19 (15–22)            | 20 (13–21)                     | 21 (17–24)                     | 18 (15–21)                       | .21     |
| Tissue characterization                         |                       |                                |                                |                                  |         |
| LGE presence†                                  | 85 (92)               | 17 (81)                        | 9 (90)                         | 59 (97)*                         | .06     |
| Subendocardial LGE†                            | 0 (0)                 | 0 (0)                          | 0 (0)                          | 0 (0)                            | .99     |
| Midwall LGE†                                   | 33 (36)               | 4 (19)                         | 5 (50)                         | 24 (39)                          | .13     |
| Subepicardial LGE†                             | 51 (55)               | 13 (62)                        | 4 (40)                         | 34 (56)                          | .56     |
| Transmural LGE†                                | 1 (1)                 | 0 (0)                          | 0 (0)                          | 1 (2)                            | .99     |
| LGE extent (%)                                 | 2 (1–5)               | 1 (0–2)                        | 2 (1–2)                        | 3 (1–6)*                         | .003    |
| LGE extent (g)                                 | 3 (1–6–)              | 1 (0–3)                        | 2 (1–4)                        | 4 (1–8)*                         | .002    |
| LGE (no. of segments)                          | 3 (1–5)               | 2 (1–3)                        | 3 (1–4)                        | 3 (1–6)*                         | .04     |
| Hyperintense                                   | 67 (77)               | 15 (79)                        | 6 (75)                         | 46 (77)                          | .99     |
| T2-weighted signal†                             |                       |                                |                                |                                  |         |
| Septal T2 z score†                             | 0.6 (–0.5 to 1.8)     | –0.3 (–0.7 to 1.5)             | 0.9 (–0.1 to 1.3)              | 0.9 (–0.1 to 2.0)                | .13     |
| Maximum T2 z score†                            | 2.7 (1.6–3.8)         | 2.7 (2.2–3.1)                  | 2.7 (1.6–3.2)                  | 3.1 (1.5–4.4)                    | .37     |
| High T2†                                       | 61 (69)               | 16 (76)                        | 7 (70)                         | 38 (66)                          | .70     |
| Septal native T1 z score†                      | 1.4 (0.2–3.1)         | 0.4 (–0.2 to 0.6)              | 1.5 (0.8–2.4)*                 | 2.2 (0.7–4.1)*                   | <.001   |
| Maximum native T1 z score†                     | 3.7 (2.3–5.7)         | 2.3 (0.6–3.1)                  | 4.0 (2.9–4.7)*                 | 4.3 (2.8–7.2)*                   | <.001   |
| High native T1†                                 | 71 (81)               | 14 (67)                        | 9 (90)                         | 48 (84)                          | .20     |
| Pericardium†                                    |                       |                                |                                |                                  |         |
| Pericardial enhancement                        | 39 (42)               | 9 (43)                         | 3 (30)                         | 27 (44)                          | .77     |
| Pericardial edema                              | 35 (38)               | 4 (19)                         | 3 (30)                         | 28 (46)                          | .07     |
| Pericardial effusion                           | 33 (36)               | 4 (19)                         | 1 (10)                         | 28 (46)                          | .02     |
| Time from symptom onset to MRI (d)             | 11 (4–29)             | 13 (5–61)                      | 45 (13–95)                     | 7 (3–20)                         | .001    |

Note.—Except where indicated, data are medians with IQRs in parentheses. P values for the three-group comparison were derived using one-way analysis of variance and the Kruskal-Wallis test or Fisher exact test, as appropriate for the type of data. GCS = global circumferential strain, GLS = global longitudinal strain, GRS = global radial strain, LGE = late gadolinium enhancement, LVEDVI = left ventricular end-diastolic volume indexed to body surface area, LVEF = left ventricular ejection fraction, LVESVI = left ventricular end-systolic volume indexed to body surface area, LVMI = left ventricular mass index, RVEDVI = right ventricular end-diastolic volume indexed to body surface area, RVEF = right ventricular ejection fraction, RVESVI = right ventricular end-systolic volume indexed to body surface area.

* Post hoc test for comparison with the COVID-19 vaccine group; statistically significant at P < .05.
† Data are numbers of patients, with percentages in parentheses.
‡ Data were available in 87 patients (19 with vaccine-associated myocarditis, eight with COVID-19 illness, and 60 with other myocarditis).
§ Data were available in 89 patients (21 with vaccine-associated myocarditis, 10 with COVID-19 illness, and 58 with other myocarditis).
|| Data were available in 88 patients (21 with vaccine-associated myocarditis, 10 with COVID-19 illness, and 57 with other myocarditis).
Myocardial Injury Pattern at MRI in COVID-19 Vaccine–associated Myocarditis

At follow-up, all 21 patients (100%) were asymptomatic; eight of 21 (38%) had normal troponin levels, nine of 21 (43%) had reduced but still mildly elevated troponin levels, and four of 21 did not have follow-up troponin levels available. Of the six patients with impaired LVEF at MRI, four underwent subsequent trans-thoracic echocardiography or follow-up MRI, which demonstrated normal LVEFs in all. No patient with vaccine-associated myocarditis had an adverse cardiac event over the short-term follow-up.

Among the 71 patients with COVID-19 illness and other myocarditis, seven and 42 had clinical follow-up for a median of 211 days (IQR, 94–295 days) and 195 days (IQR, 87–415 days), respectively. The COVID-19 illness group included three major adverse cardiovascular events (one hospitalization for heart failure and two arrhythmia events [one patient subsequently underwent placement of an implantable cardioverter-defibrillator]), while the other myocarditis group included five major adverse cardiovascular events (two hospitalizations for heart failure and three arrhythmia events [four patients subsequently underwent placement of an implantable cardioverter-defibrillator]). There were no deaths in any group. As expected, the follow-up duration for the other two groups was much longer than that for the vaccine group, given the relatively short amount of time that COVID-19 vaccines had been administered.

Discussion

In this retrospective cohort study of 92 patients who met both clinical and imaging diagnostic criteria for acute myocarditis, we identified 21 patients with myocarditis following
COVID-19 vaccine administration who were younger and more frequently male compared with 10 patients who had recovered from COVID-19 illness and 61 patients with other causes of myocarditis. To our knowledge, this is the first report of cardiac MRI findings in hospitalized and nonhospitalized patients with myocarditis following COVID-19 vaccination in comparison with patients with other causes of myocarditis, including COVID-19 illness. Abnormal MRI findings among patients with myocarditis following COVID-19 vaccination included late gadolinium enhancement (LGE) in 81%, high T1 in 67%, high T2 in 76%, and systolic left ventricular dysfunction in 29%. MRI revealed a similar pattern of myocardial injury in patients with myocarditis following COVID-19 vaccination compared with that of other causes, including subepicardial LGE and edema at the basal inferior lateral wall, although patient demographics differed and abnormalities were less severe. Patients with vaccine-associated myocarditis had higher left ventricular ejection fraction and lower native T1 values compared with those

![Figure 3](image-url) Scatterplots show (A) left ventricular ejection fraction (LVEF), (B) late gadolinium enhancement (LGE), (C) native T1, and (D) native T2 according to patient group. Graphs for MRI parameters depict individual patient data points with error bars displayed as medians and IQRs. There were significant differences in the maximum native T1 z score, maximum native T2 z score, and LGE extent (as a percentage of left ventricular mass) between patients with vaccine-associated myocarditis [vaccine] and those with other myocarditis [other]. All other comparisons between patients with vaccine-associated myocarditis and patients with COVID-19 illness (COVID-19) or other myocarditis were not significant [ns]. *** = P < .05; statistically significant.

**Table 3: Univariable and Multivariable Linear Regression Parameters with Vaccine-associated Myocarditis as the Reference Group**

| Parameter                      | COVID-19 Illness | Other Myocarditis | Univariable models | Multivariable models |
|-------------------------------|------------------|-------------------|--------------------|----------------------|
| LVEF (%)                      | −6.1 (−11.3, −0.9) | −5.3 (−7.9, −2.6) | 0.024              | 0.003                |
| GLS (%)                       | 1.1 (−1.6, 3.9)  | 1.9 (0.9, 3.0)    | 0.41               | 0.001                |
| GCS (%)                       | 1.3 (−1.0, 3.7)  | 2.0 (1.0, 2.9)    | 0.26               | <0.001               |
| GRS (%)                       | −2.2 (−7.4, 2.9) | −3.6 (−5.5, −1.8) | 0.38               | <0.001               |
| Maximum T1 z score            | 2.6 (1.0, 4.2)   | 1.7 (0.7, 2.9)    | 0.003              | 0.002                |
| Maximum T2 z score            | 0.1 (0.9, 1.1)   | 0.5 (−0.1, 1.1)   | 0.79               | 0.12                 |
| LGE extent, no. of segments   | 1.1 (−0.5, 2.7)  | 1.2 (0.3, 2.1)    | 0.19               | 0.012                |

**Note.**—Data in parentheses are 95% CIs. Linear regression was used to evaluate the relationship between continuous MRI parameters and the patient group in univariable and multivariable models controlling for patient age, sex, and time from symptom onset to MRI. GCS = global circumferential strain, GLS = global longitudinal strain, GRS = global radial strain, LGE = late gadolinium enhancement, LVEF = left ventricular ejection fraction.

* Average difference in the magnitude of each MRI parameter (dependent variable) between COVID-19 illness–associated myocarditis and COVID-19 vaccination–associated myocarditis (independent variable; vaccine-associated myocarditis is the reference group).

† Average difference in the magnitude of each MRI parameter (dependent variable) between other causes of myocarditis and COVID-19 vaccination–associated myocarditis (independent variable; vaccine-associated myocarditis is the reference group).

‡ Individual multivariable linear regression models for each MRI parameter (as the dependent variable) and disease group (as the independent variable) were adjusted for patient age, sex, and time from symptom onset to MRI.
with COVID-19 illness and other causes of myocarditis, and they demonstrated rapid clinical improvement with no adverse events over short-term follow-up.

Our observations are concordant with case series of hospitalized patients reporting that most patients with vaccine-associated myocarditis were younger men presenting after the second vaccine dose, with frequent presence of LGE and myocardial edema on MRI scans and rapid improvement in clinical symptoms at short-term follow-up (10,11,24). Other MRI findings in our cohort included high T1 and T2 mapping values and impaired myocardial strain. T1 and T2 mapping are quantitative tissue characterization techniques that provide complementary information, particularly in the setting of myocardial inflammation. High T2 is specific for increased tissue water and can help discriminate between active and healed myocarditis (25). Native T1 is also elevated in the setting of edema, although unlike T2, this change is not specific for acute inflammation and can alternatively reflect fibrosis or infiltration. This might account for the significant correlation between peak troponin level and native T1, which is associated with better prognosis compared with native T1, in our study.

Unlike prior reports, our findings demonstrate that myocardial injury was detectable in patients with acute myocarditis who did not require hospital admission and the severity of MRI abnormalities was milder, in general, compared with that of patients with other causes of myocarditis, even after controlling for age, sex, and time from symptom onset to imaging. Patients with myocarditis following COVID-19 illness had a lower LVEF, higher prevalence of regional left ventricular dysfunction, and higher native T1 compared with those with vaccine-associated myocarditis, although other MRI parameters did not differ significantly. This suggests that the imaging phenotype of patients with COVID-19–related myocardial injury may be intermediate between vaccine-associated myocarditis and other causes.

Presentation after the second vaccine dose or after the first dose in the context of prior SARS-CoV-2 infection in most patients indicates that prior exposure is relevant and necessitates continued surveillance for postvaccination myocarditis, particularly following booster doses. Although non-mRNA vaccines were also administered in Canada, all patients with vaccine-associated myocarditis in our cohort presented after receiving an mRNA-based COVID-19 vaccine. The mechanisms by which a host’s immunologic response to mRNA-based COVID-19 vaccination could lead to myocarditis in a small minority of patients warrants further study, particularly because other mRNA-based vaccines and therapies are in development (26,27).

Milder MRI abnormalities in patients with vaccine-associated myocarditis compared with other causes raises the possibility that this group may have a lower future adverse event rate. Lack of any adverse events in our patients with vaccine-associated myocarditis over short-term follow-up is reassuring. However, longer-term follow-up is needed, particularly given the association of LGE with adverse cardiac events in nonvaccine-associated myocarditis (28,29). Interestingly, one prior study found that patchy and midwall, but not subepicardial, patterns of LGE were associated with adverse events in patients with nonvaccine-associated myocarditis (30). Similarly, a septal but not lateral LGE location was associated with major adverse cardiac events (30). This requires further investigation given that the majority of patients with vaccine-associated myocarditis in our study had a subepicardial pattern of LGE with a predilection for the basal to mid-lateral wall and infrequent involvement of the septum, which may be associated with relatively favorable outcomes. LGE usually reflects fibrosis in ischemic and nonischemic cardiomyopathies; however, in patients with acute myocarditis it often reflects an increased volume of distribution of the gadolinium-based contrast agent in the affected region related to myocyte necrosis and edema. In all patients with vaccine-associated myocarditis, LGE colocalized with edema in at least one segment, which is associated with better prognosis compared with isolated LGE without T2 hyperintensity and confers the possibility of recovery as edema improves with time (31).

Our study has limitations, including a modest sample size and a short follow-up for patients with myocarditis following vaccination. More than one MRI scanner was used for imaging, which impacts quantitative parametric mapping. To address this, we interpreted mapping values in the context of scanner-specific local reference ranges and calculated z scores for T1 and T2 values. The timing of MRI after symptom onset varied, which could impact detection of myocardial edema as MRI markers of edema typically demonstrate rapid improvement during the first few weeks after symptom onset (32). There were also significant differences in patient age and sex between groups. Although...
we adjusted for age, sex, and timing of imaging in our analysis, it is possible that this did not fully account for differences between groups. Only midventricular T1 and T2 mapping sections were examined, which could underestimate maximum T1 and T2 values if regional disease was only present in other areas of the myocardium. However, LGE and T2-weighted imaging were performed with coverage of the entire myocardium from base to apex. This may account for the overall slightly higher prevalence of abnormalities on LGE and T2-weighted images compared with T1 and T2 mapping, respectively. As this was not a population-based study, we could not calculate the incidence of vaccine-associated myocarditis. There is no standardized definition of vaccine-associated myocarditis or COVID-19–related myocardial injury in the literature to date, particularly with respect to the timing of symptom onset after vaccine administration or COVID-19 diagnosis. For consistency, we used the same 14-day interval between vaccination or COVID-19 diagnosis to symptom onset to define both groups. Finally, histologic confirmation of myocarditis was not available as endomyocardial biopsy is not frequently performed at our center unless there is clinical evidence that the results will have a meaningful effect on therapeutic decisions (33). Our findings should be confirmed in future large, multicenter studies with longer-term follow-up.

In conclusion, our study results demonstrate that the pattern of MRI abnormalities in COVID-19 vaccine–associated myocarditis was similar to that of other causes, although patient demographics differed and MRI findings tended to be less severe. Overall, our study findings are generally consistent with an imaging phenotype that has good prognostic; however, further studies are needed to examine the long-term effects of mRNA-based COVID-19 vaccination on the heart, to determine the risk associated with booster doses, and to inform recommendations for vaccination in patients with a history of myocarditis.

Author contributions: Guarantors of integrity of entire study, M.E., K.H.; study concepts/study design or data acquisition or data analysis/interpretation, all authors; manuscript drafting or manuscript revision for important intellectual content, all authors; agrees to ensure any questions related to the work are appropriately resolved, all authors; literature research, M.F., K.H.; clinical studies, M.F., V.C., R.H., K.H.; experimental studies, M.E.; statistical analysis, M.E., P.T., K.H.; and manuscript editing, M.E., P.T., V.C., G.R.K., J.A.U., R.M.W., K.H.

Disclosures of conflicts of interest: M.F. No relevant relationships. P.T. No relevant relationships. V.C. No relevant relationships. G.R.K. No relevant relationships. J.A.U. Grants from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Novartis, Sanofi; consultant, Boehringer Ingelheim, Novartis, Sanofi; honoraria from GlaxoSmithKline and Sanofi. R.M.W. No relevant relationships. R.H. No relevant relationships. K.H. Honoraria from Sanofi Genzyme, Amicus, and Medscape.

References

1. Sanchez Tijmes F, Thavendiranathan P, Udell JA, Seidman MA, Hanneman K. Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination. Radiol Cardiothorac Imaging 2021;3(6):e210252.
2. Azetz HT, Billingham ME, Edwards WD, et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1987;1(1):3–14.
3. Ammiriti E, Cipriani M, Moro C, et al. Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis: Multicenter Lombardy Registry. Circulation 2018;138(11):1088–1099.
4. Su JR, McNeil MM, Welsh KJ, et al. Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018. Vaccine 2021;39(5):839–845.
5. Luk A, Clarke B, Dohdah N, et al. Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. Circ J Cardiovasc Med 2021;37(1):139–163.
6. Holder J. The New York Times Tracking Coronavirus Vaccinations Around the World. https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html. Published Jan. 29, 2021. Accessed December 15, 2021.
7. Giustino G, Croft LB, Stefanini GG, et al. Characterization of Myocardial Injury in Patients With COVID-19. J Am Coll Cardiol 2020;76(18):2043–2055.
8. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020;5(7):811–818.
9. Pan JA, Lee YJ, Salerno M. Diagnostic Performance of Extracellular Volume, Native T1, and T2 Mapping Versus Lake Louise Criteria by Cardiac Magnetic Resonance for Detection of Acute Myocarditis: A Meta-Analysis. Circ Cardiovasc Imaging 2018;11(7):e007598.
10. Kim HW, Jenista ER, Wendell DC, et al. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol 2021;6(10):1196–1201.
11. Montgomery J, Ryan M, Engler R, et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol 2021;6(10):1202–1206.
12. Starekova J, Bluenke DA, Bradham WS, Geist TM, Schiebler ML, Reeder SB. Myocarditis Associated with mRNA COVID-19 Vaccination. Radiolology 2021;301(2):E409–E411.
13. Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34(53):2636–2648, 2648a–2648d.
14. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol 2018;72(24):3158–3176.
15. Jain SS, Steele JM, Fonseca B, et al. COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics 2021;148(5):e2021354327.
16. Voinys I, Baristaite G, Gurwitz D. Effects of age and sex on recovery from COVID-19: Analysis of 5769 Israeli patients. J Infect 2020;88(2):e102–e103.
17. Kellman P, Arzai AE. Cardiac imaging techniques for physicians: late enhancement. J Magn Reson Imaging 2013;15(1):56.
18. Kellman P, Arzai AE, Xue H. T1 and extracellular volume mapping in the heart: estimation of error maps and the influence of noise on precision. J Cardiovasc Magn Reson 2013;15(1):56.
19. Wassmuth R, Prothmann M, Utz W, et al. Variability and homogeneity of cardiovascular magnetic resonance myocardial T2-mapping in volunteers compared to patients with edema. J Cardiovasc Magn Reson 2013;15(1):27.
20. Schulz-Menger J, Bluenke DA, Bremerich J, et al. Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update : Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post-Processing. J Cardiovasc Magn Reson 2020;22(1):19.
21. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105(4):539–542.
22. Metsooglou DR, Moon JC, Ferreira VM, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI), J Cardiovasc Magn Reson 2017;19(1):75. [Published correction appears in J Cardiovasc Magn Reson 2018;20(1):9].
23. Thavendiranathan P, Zhang L, Zafar A, et al. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Coll Cardiol 2021;77(12):1503–1516.
24. Dionne A, Sperotto F, Chamberlain S, et al. Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children. JAMA Cardiol 2021;6(12):1446–1450.
25. Galán-Arriola C, Lobo M, Vilchez-Tschischke JP, et al. Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity. J Am Coll Cardiol 2019;73(7):779–791.
26. Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer 2021;20(1):41.
27. Pandi N, Hogan MJ, Poole FY, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 2018;17(4):261–279.
28. Grün S, Schumm J, Greulich S, et al. Long-term follow-up of biopsy-proven viral myocarditis predictors of mortality and incomplete recovery. J Am Coll Cardiol 2012;59(18):1604–1615.

29. Yang F, Wang J, Li W, et al. The prognostic value of late gadolinium enhancement in myocarditis and clinically suspected myocarditis: systematic review and meta-analysis. Eur Radiol 2020;30(5):2616–2626.

30. Gräni C, Eichhorn C, Bière L, et al. Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis. J Am Coll Cardiol 2017;70(16):1964–1976 [Published correction appears in J Am Coll Cardiol 2017;70(21):2736.].

31. Aquaro GD, Ghebru Habtemicael Y, Camastra G, et al. Prognostic Value of Repeating Cardiac Magnetic Resonance in Patients With Acute Myocarditis. J Am Coll Cardiol 2019;74(20):2439–2448.

32. Luetkens JA, Homsi R, Dabir D, et al. Comprehensive Cardiac Magnetic Resonance for Short-Term Follow-Up in Acute Myocarditis. J Am Heart Assoc 2016;5(7):e003603.

33. Cooper IT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. J Am Coll Cardiol 2007;50(19):1914–1931.